VOLUME 59   1998   SUPPLEMENT 3

Articles

3 Reducing Clozapine-Related Morbidity and Mortality: 5 Years of Experience With the Clozaril National Registry. Gilbert Honigfeld, Ph.D., Felix Arellano, M.D., Jitender Sethi, Ph.D., Anthony Bianchini, and Jeffrey Schein, Dr.P.H., M.P.H.
[Abstract] [PDF]

8 Clozapine Reduces Violence and Persistent Aggression in Schizophrenia. William M. Glazer, M.D., and Ruth A. Dickson, M.D.
[Abstract] [PDF]

15 Suicide in Schizophrenia: Risk Factors and Clozapine Treatment. Herbert Y. Meltzer, M.D.
[Abstract] [PDF]

21 Facilitating Compliance With Antipsychotic Medication. Stephen R. Marder, M.D.
[Abstract] [PDF]

26 Substance Abuse in Schizophrenia: A Review. Peter F. Buckley, M.D.
[Abstract] [PDF]

31 Effects of Clozapine Therapy in Schizophrenic Individuals at Risk for Tardive Dyskinesia. Daniel E. Casey, M.D.
[Abstract] [PDF]

38 Maximizing Clozapine Therapy: Managing Side Effects. Jeffrey A. Lieberman, M.D.
[Abstract] [PDF]

44 Optimizing Treatment With Clozapine. Robert R. Conley, M.D.
[Abstract] [PDF]